ˇ
M. Lukác et al. / Bioorg. Med. Chem. Lett. 19 (2009) 6346–6349
6349
26. Coghi, P.; Vaiana, N.; Pezzano, M. G.; Rizzi, L.; Kaiser, M.; Brun, R.; Romeo, S.
Bioorg. Med. Chem. Lett. 2008, 18, 4658.
27. Hornillos, V.; Carrillo, E.; Rivas, L.; Amat-Guerri, F.; Acuña, A. U. Bioorg. Med.
Chem. Lett. 2008, 18, 6336.
28. Wadhone, P.; Maiti, M.; Agarwal, R.; Kamat, V.; Martin, S.; Saha, B. J. Immunol.
2009, 182, 7146.
29. Croft, S. L.; Snowdon, W.; Yardley, V. J. Antimicrob. Chemother. 1996, 38, 1041.
30. Walochnik, J.; Duchêne, M.; Seifert, K.; Obwaller, A.; Hottkowitz, T.;
Wiedremann, G.; Eibl, H.; Aspöck, H. Antimicrob. Agents Chemother. 2002, 46,
695.
In conclusion, we have described synthesis of 15 DAPCs. Their
biological activity was compared with HPC and biscationic surfac-
tant 16. The antiprotozoal activity was determined against A. lug-
dunensis. Compound 15 exhibited excellent trophocidal activity.
The antifungal activity was determined against C. albicans. None
of the tested DAPCs exhibited better activity than HPC. The cyto-
toxicity was determined against Hfl-1 and HeLa. The most cyto-
toxic was compound 10, which was more active against tumor
cells as against normal cells.
31. McBride, J.; Ingram, P. R.; Henriquez, F. L.; Roberts, C. J. Clin. Microbiol. 2005, 43,
629.
32. Schuster, F. L.; Guglielmo, B. J.; Visvesvara, G. S. J. Eukaryot. Microbiol. 2006, 53,
121.
33. McBride, J.; Mullen, A. B.; Carter, K. C.; Roberts, C. W. J. Antimicrob. Chemother.
2007, 60, 521.
Acknowledgments
This work was partially supported by Grants: FaF UK/30/2009
UK/110/2008, CNMP PN II 42147/2008, VEGA 1/4300/07, VEGA1/
4290/07, VEGA 1/0164/08 and VEGA 1/4341/07.
ˇ
34. Lukác, M.; Mrva, M.; Ondriska, F.; Lacko, I.; Devínsky, F. Chem. Listy 2008, 102,
s199.
35. Aichelburg, A. C.; Walochnik, J.; Assadian, O.; Prosch, H.; Steuer, A.; Perneczky,
G.; Visvesvara, G. S.; Aspöck, H.; Vetter, N. Emerg. Infect. Dis. 2008, 14, 1743.
36. Walochnik, J.; Obwaller, A.; Gruber, F.; Mildner, M.; Tschachler, E.; Suchomel,
M.; Duchêne, M.; Auer, H. J. Antimicrob. Chemother. 2009, 64, 539.
37. Seifert, K.; Duchêne, M.; Wernsdorfer, W. H.; Kollaritsch, H.; Scheiner, O.;
Wiedermann, G.; Hottkowitz, T.; Eibl, H. Antimicrob. Agents Chemother. 2001,
45, 1505.
38. Blaha, C.; Duchêne, M.; Aspöck, H.; Walochnik, J. J. Antimicrob. Chemother. 2006,
57, 273.
39. Steinberg, J. P.; Galindo, R. L.; Kraus, E. S.; Ghanem, K. G. Clin. Infect. Dis. 2002,
35, e43.
40. Duarte, A. G.; Sattar, F.; Granwehr, B.; Aronson, J. F.; Wang, Z.; Lick, S. J. Heart
Lung Transplant. 2006, 25, 237.
41. Fürnkranz, U.; Nagl, M.; Gottardi, W.; Köhsler, M.; Aspöck, H.; Walochnik, J.
Antimicrob. Agents Chemother. 2008, 52, 470.
42. Croft, S. L.; Seifert, K.; Duchêne, M. Mol. Biochem. Parasitol. 2003, 126, 165.
43. Lorenzo-Morales, J.; Kliešciková, J.; Martinez-Carretero, E.; De Pablos, L. M.;
References and notes
1. Houlihan, W. J.; Lohmeyer, M.; Workman, P.; Cheon, S. H. Med. Res. Rev. 1995,
15, 157.
2. Brachwitz, H.; Vollgraf, C. Pharmacol. Ther. 1995, 66, 39.
3. Koufaki, M.; Polychroniou, V.; Calogeropoulou, T.; Tsotinis, A.; Drees, M.; Fiebig,
H. H.; LeClerc, S.; Hendriks, H. R.; Makriyannis, A. J. Med. Chem. 1996, 39, 2609.
4. Hilgard, P.; Klenner, T.; Stekar, J.; Nössner, G.; Kutscher, B.; Engel, J. Eur. J.
Cancer 1997, 33, 442.
5. Nair, H. K.; Peterson, A. C.; Yazdi, P. T.; Franzmair, R. Bioorg. Med. Chem. Lett.
1997, 7, 2379.
´
ˇ
´
6. Holy, A.; Otová, B.; Budešínsky, M.; Emerson, D.; Wiles, M. E. J. Med. Chem.
2001, 44, 4462.
ˇ
7. Papazafiri, P.; Avlonitis, N.; Angelou, P.; Calogeropoulou, T.; Koufaki, M.;
Scoulica, E.; Fragiadaki, I. Cancer Chemother. Pharmacol. 2005, 56, 261.
8. Pinchuk, A. N.; Rampy, M. A.; Longino, M.; Skinner, R. W. S.; Gross, M. D.;
Weichert, J. P.; Counsell, R. E. J. Med. Chem. 2006, 49, 2155.
´
Profotová, B.; Nohynková, E.; Osuna, A.; Valladares, B. Eukaryot. Cell 2008, 7,
509.
44. Peresypkin, A. V.; Menger, F. M. Org. Lett. 1999, 1, 1347.
45. Kumar, A.; Alami, E.; Holmberg, K.; Seredyuk, V.; Menger, F. M. Colloids Surf. A:
Physicochem. Eng. Asp. 2003, 228, 197.
46. Seredyuk, V.; Alami, E.; Nydén, M.; Holmberg, K.; Peresypkin, A. V.; Menger, F.
M. Langmuir 2001, 17, 5160.
47. Seredyuk, V.; Alami, E.; Nydén, M.; Holmberg, K.; Peresypkin, A. V.; Menger, F.
M. Colloids Surf. A: Physicochem. Eng. Asp. 2002, 203, 245.
48. Sun, Y.; Feng, Y.; Dong, H.; Chen, Z.; Han, L. Cent. Eur. J. Chem. 2007, 5, 620.
49. Menger, F. M.; Seredyuk, V. A.; Apkarain, R. P.; Wright, E. R. J. Am. Chem. Soc.
2002, 124, 12408.
50. Ukawa, K.; Imamiya, E.; Yamamoto, H.; Mizuno, K.; Tasaka, A.; Terashita, Z.;
Okutani, T.; Nomura, H.; Kasukabe, T.; Hozumi, M.; Kudo, I.; Inoue, K. Chem.
Pharm. Bull. 1989, 37, 1249.
9. Gajate, C.; Gonzales-Camacho, F.; Mollinedo, F. Plos 1 2009, 4, e5044.
ˇ
ˇ
ˇ
10. Lukác, M.; Mojziš, J.; Mojzišová, G.; Mrva, M.; Ondriska, F.; Valentová, J.; Lacko,
I.; Bukovsky´, M.; Devínsky, F.; Karlovská, J. Eur. J. Med. Chem., in press.
11. Mollinedo, F.; Fernandez-Luna, J. L.; Gajate, C.; Martin-Martin, B.; Benito, A.;
Martinez-Dalmau, R.; Modolell, M. Cancer Res. 1997, 57, 1320.
12. Gajate, C.; Fonteriz, R. I.; Cabaner, C.; Alvarez-Noves, G.; Alvarez-Rodriquez, Y.;
Modolell, M.; Mollinedo, F. Int. J. Cancer 2000, 85, 674.
13. Gajate, C.; Mollinedo, F. Blood 2001, 98, 3860.
14. Gajate, C.; Del Canto-Janez, E.; Acuña, A. U.; Amat-Guerri, F.; Geijo, E.; Santos-
Beneit, A. M.; Veldman, R. J.; Mollinedo, F. J. Exp. Med. 2004, 200, 353.
15. Gajate, C.; Mollinedo, F. Blood 2007, 109, 711.
16. Leonard, R.; Hardy, J.; van Tienhoven, G.; Houston, S.; Simmononds, S.; David,
M.; Mansi, J. Clin. Oncol. 2001, 19, 4150.
17. Vink, S. R.; Schellens, J. H.; van Blitterswijk, W. J.; Verheij, M. Invest. New Drugs
2005, 23, 279.
18. Obando, D.; Widmer, F.; Wright, L. C.; Sorrell, T. C.; Jolliffe, K. A. Bioorg. Med.
Chem. 2007, 15, 5158.
19. Widmer, F.; Wright, L. C.; Obando, D.; Handke, R.; Ganandren, R.; Ellis, D. H.;
Sorrell, T. C. Antimicrob. Agents Chemother. 2006, 50, 414.
20. Tong, Z.; Widmer, F.; Sorrell, T. C.; Guse, Z.; Jolliffe, K. A.; Halliday, C.; Lee, O. C.;
Kong, F.; Wright, L. C.; Chen, S. C. A. Antimicrob. Agents Chemother. 2007, 51, 2219.
21. Bierer, D. E.; Garber, R. E.; Jolad, S. D.; Ubillas, R. P.; Randle, J.; Nauka, E.; Latour,
J.; Dener, J. M.; Fort, D. M.; Kuo, J. E.; Inman, W. D.; Dubenko, L. G.; Ayala, F.;
Ozioko, A.; Obialor, C.; Elisabetsky, E.; Carlson, T.; Truong, T. V.; Bruening, R. C.
J. Org. Chem. 1995, 60, 7022.
22. Lu, Q.; Ubillas, R. P.; Zhou, Y.; Dubenko, L. G.; Dener, J. M.; Litvak, J.; Phuan, P.
W.; Flores, M.; Ye, Z. J.; Gerber, R. E.; Truong, T.; Biere, D. E. J. Nat. Prod. 1999, 62,
824.
23. Hornillos, V.; Saugar, J. M.; de la Torre, B. G.; Andreu, D.; Rivas, L.; Acuña, A. U.;
Amat-Guerri, F. Bioorg. Med. Chem. Lett. 2006, 16, 5190.
51. McKennon, M. J.; Meyers, A. I.; Darauz, K.; Schwarm, M. J. Org. Chem. 1993, 58,
3568.
52. Clarke, H. T.; Gillespie, H. B.; Weisshaus, S. Z. J. Am. Chem. Soc. 1933, 55, 4571.
ˇ
53. Imam, T.; Devínsky, F.; Lacko, I.; Mlynarcík, D. Pharmazie 1983, 38, 308.
ˇ
54. Lukác, M.; Lacko, I.; Devínsky, F. Acta Facult. Pharm. Univ. Comenianae 2008, 55,
141.
55. Characterization of compound 5: 1H NMR (CDCl3, TMS) d 0.84–0.92 (m, 6H),
1.18–1.41 (m, 32H), 1.55–1.78 (m, 4H), 2.18 (s, 2H), 3.35 (s, 6H), 3.41–3.50 (m,
2H), 3.76–3.89 (m, 4H), 4.27–4.35 (m, 2H); 13C NMR (CDCl3, TMS) d 14.1, 22.7,
22.9, 26.0, 26.3, 29.3, 29.4, 29.5, 29.6, 29.7, 31.0, 31.1, 31.9, 51.9, 58.8, 64.2,
65.5, 65.6, 65.9; 31P NMR (CDCl3, H3PO4) d 0.76; IR max/cmÀ1 3427, 2919, 2851,
m
1635, 1469, 1242, 1100, 1067, 822.
ˇ
56. Ondriska, F.; Mrva, M.; Lichvár, M.; Ziak, P.; Murgašová, Z.; Nohy´nková, E. Ann.
Agric. Environ. Med. 2004, 11, 335.
57. Fischer-Fodor, E.; Moldovan, N.; Virag, P.; Soritau, O.; Brie, I.; Lonnecke, P.; Hey-
Hawkins, E.; Silaghi-Dumitrescu, L. Dalton Trans. 2008, 45, 6393.
58. HeLa cells were cultivated using Dulbecco’s Modified Eagle’s medium. For the
IC50 measurements, cells were seeded on 96-well cell culture plates in a
concentration of 10,000 cells per well, in 200 ll of cell culture media.
Compounds were dissolved in Ca- and Mg-free phosphate buffered saline
(PBS) solution in stock concentrations (10 mg/ml). In order to obtain the IC50
values, the experiments for all compounds were performed for a concentration
24. Seifert, K.; Lemke, A.; Croft, S. L.; Kayser, O. Antimicrob. Agents Chemother. 2007,
51, 4525.
25. Calogeropoulou, T.; Angelou, P.; Detsi, A.; Fragiadaki, I.; Scoulica, E. J. Med.
Chem. 2008, 51, 897.
series (from 1 to 200 lg/ml).